Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A company founded on decades of research regarding C-peptide and long-term complications of type 1 diabetes is in phase 2 trials of a once-weekly C-peptide replacement therapy and is raising fresh capital.
Cebix is developing a disease-modifying treatment for diabetic peripheral neuropathy, which it thinks could eventually be used as a treatment for all microvascular complications of diabetes. The therapy is Ersatta, a long-acting form of C-peptide designed to be administered once-weekly.
http://medcitynews.com/2012/10/to-p...f-type-1-diabetes-company-looks-to-c-peptide/
Cebix is developing a disease-modifying treatment for diabetic peripheral neuropathy, which it thinks could eventually be used as a treatment for all microvascular complications of diabetes. The therapy is Ersatta, a long-acting form of C-peptide designed to be administered once-weekly.
http://medcitynews.com/2012/10/to-p...f-type-1-diabetes-company-looks-to-c-peptide/